TGFB1 and hepatocellular carcinoma: Further analysis of VD treatment in human cirrhosis and hepatocellular cancer revealed that VD treatment restored expression levels of TGF-β pathway members and destabilized β-catenin, suggesting that patients with an inactivated TGF-β signature could potentially benefit from VD treatment.